Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jilin Aodong Defers Investment in Vital Therapies

publication date: Dec 15, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jilin Aodong Medicine (吉林敖东药业集团股份有限公司) has put a hold on its $25 million investment in Vital Therapies, a US medical device maker, pending SFDA approval of Vital Therapies’ Extracorporeal Liver Assist Device (ELAD). In May, Jilin Aodong paid $2 million for a 5% stake in Vital Therapies. The deal included a provision for an additional $25 million investment after six months, contingent on SFDA approval of the ELAD, which hasn’t taken place. More details....

Stock Symbol: (SHE: 000623)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors